Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 8/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.42 |
| ▸ | ARG2 | P78540 | 4/20 | 0.41 |
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | OTC | P00480 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19246101 | 0.92 | GSR (0.56) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL20192789 | 0.89 | GSR (0.56) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL24945952 | 0.88 | GSR (0.53) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL22375753 | 0.88 | GSR (0.53) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL18924694 | 0.88 | GSR (0.53) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL20192790 | 0.86 | GSR (0.50) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL7803301 | 0.82 | ACHE (0.62) | ACHENOD1 | |
| SCHEMBL7797292 | 0.82 | ACHE (0.62) | ACHENOD1 | |
| SCHEMBL15618155 | 0.82 | GSR (0.40) | GSRACHEDDAH1ARG2ARG1 | |
| SCHEMBL7804961 | 0.82 | ACHE (0.62) | ACHENOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253345-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2019-04-09 | — | — | US | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170306380-A1 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-9732367-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9670521-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253345-B2 | Cell lines | AARS1, LARS1, IARS1 | GSR 1724/4885ACHE 4880/4885DDAH1 3832/4885 |
| US-20170306381-A1 | CELL LINES | AARS1, LARS1, IARS1 | GSR 1724/4885ACHE 4880/4885DDAH1 3832/4885 |
| US-20170306380-A1 | AMINO ACID DERIVATIVES | BCAT2, DNPEP, BCAT1 | GSR 3690/4885ACHE 3823/4885DDAH1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.